• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

度普利尤单抗用于治疗肺动脉高压持续静脉输注前列环素所致皮肤并发症:一例报告及文献综述

Use of Dupilumab to Treat Cutaneous Complications of Continuous Prostacyclin Infusion in Pulmonary Hypertension: A Case Report and Review of Literature.

作者信息

Varghese Nidhy P, Ely Erin, Fombin Rozmeen, Champion Claire, Whalen Elise

机构信息

Department of Pediatrics, Division of Pulmonology Baylor College of Medicine Houston Texas USA.

Texas Children's Hospital Pulmonary Hypertension Center at the Texas Medical Center Houston Texas USA.

出版信息

Pulm Circ. 2025 Sep 12;15(3):e70158. doi: 10.1002/pul2.70158. eCollection 2025 Jul.

DOI:10.1002/pul2.70158
PMID:40948577
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12426413/
Abstract

Adhesive reactions are common complications of continuous treprostinil infusions, limiting their recommended use as a treatment for severe pulmonary hypertension. We present the case of a 10-year-old male with recurrent adhesive-related skin reactions, which compromised both subcutaneous and intravenous continuous treatment. Due to comorbid atopic dermatitis (AD), dupilumab was initiated to decrease skin reactions to adhesives. Within 48 h of initiation, skin reactions completely resolved. With sustained dupilumab treatment, he remains symptom-free and is successfully tolerating intravenous treprostinil infusion.

摘要

黏附反应是持续输注曲前列尼尔常见的并发症,限制了其作为重度肺动脉高压治疗的推荐应用。我们报告了一例10岁男性患者,其反复出现与黏附相关的皮肤反应,这影响了皮下和静脉连续治疗。由于合并特应性皮炎(AD),开始使用度普利尤单抗以减少对黏附剂的皮肤反应。在开始治疗后的48小时内,皮肤反应完全消退。随着度普利尤单抗的持续治疗,他一直无症状,并且成功耐受静脉输注曲前列尼尔。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d293/12426413/ffe4406081cc/PUL2-15-e70158-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d293/12426413/ffe4406081cc/PUL2-15-e70158-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d293/12426413/ffe4406081cc/PUL2-15-e70158-g001.jpg

相似文献

1
Use of Dupilumab to Treat Cutaneous Complications of Continuous Prostacyclin Infusion in Pulmonary Hypertension: A Case Report and Review of Literature.度普利尤单抗用于治疗肺动脉高压持续静脉输注前列环素所致皮肤并发症:一例报告及文献综述
Pulm Circ. 2025 Sep 12;15(3):e70158. doi: 10.1002/pul2.70158. eCollection 2025 Jul.
2
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Conjunctivitis in Adults with Atopic Dermatitis Treated with Dupilumab: An Observational Study of Clinical Characteristics, Symptomatology, and Treatment.度普利尤单抗治疗成人特应性皮炎合并结膜炎:一项关于临床特征、症状学及治疗的观察性研究
Adv Ther. 2025 May 19. doi: 10.1007/s12325-025-03209-4.
5
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中,度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
6
Systemic treatments for eczema: a network meta-analysis.湿疹的全身治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Sep 14;9(9):CD013206. doi: 10.1002/14651858.CD013206.pub2.
7
Clinical Characteristics of Super Responders to Anti-IL-4Rα Biologic Therapy in Atopic Dermatitis.特应性皮炎中抗IL-4Rα生物疗法超级应答者的临床特征
Dermatol Ther (Heidelb). 2025 Aug 16. doi: 10.1007/s13555-025-01514-y.
8
Complete/Near-Complete Itch Response Observed in Patients with Moderate-to-Severe Atopic Dermatitis Initiating Dupilumab: 3-Year, Real-World, Interim Data from the PROSE Registry.在中度至重度特应性皮炎患者中启动度普利尤单抗治疗后观察到的完全/近乎完全瘙痒缓解:来自PROSE注册研究的3年真实世界中期数据。
Dermatol Ther (Heidelb). 2025 Jun;15(6):1523-1531. doi: 10.1007/s13555-025-01395-1. Epub 2025 Apr 15.
9
Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials.特应性皮炎患者接受度普利尤单抗治疗的感染风险:一项随机对照试验的荟萃分析。
J Am Acad Dermatol. 2018 Jan;78(1):62-69.e1. doi: 10.1016/j.jaad.2017.09.052. Epub 2017 Oct 4.
10
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.与安慰剂(“Measure Up 1”和“Measure Up 2”研究)及度普利尤单抗(“Heads Up”研究)相比,乌帕替尼可快速改善瘙痒并清除皮肤症状:三项针对中度至重度特应性皮炎患者的3期临床试验结果
Dermatol Ther (Heidelb). 2025 Jun 2. doi: 10.1007/s13555-025-01443-w.

本文引用的文献

1
Atopic Dermatitis: The Relationship Between Immune Mediators and Skin Lipid Barrier.特应性皮炎:免疫介质与皮肤脂质屏障之间的关系
Clin Rev Allergy Immunol. 2025 May 14;68(1):49. doi: 10.1007/s12016-025-09057-y.
2
Current and Emerging Biologics for Atopic Dermatitis.特应性皮炎的现有和新兴生物制剂。
Immunol Allergy Clin North Am. 2024 Nov;44(4):577-594. doi: 10.1016/j.iac.2024.08.001. Epub 2024 Sep 2.
3
Embracing the challenges of neonatal and paediatric pulmonary hypertension.拥抱新生儿和儿科肺动脉高压的挑战。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01345-2024. Print 2024 Oct.
4
Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients.小儿肺动脉高压患者无法耐受持续皮下注射曲前列尼尔。
Pulm Circ. 2023 Apr 1;13(2):e12224. doi: 10.1002/pul2.12224. eCollection 2023 Apr.
5
Atopic Dermatitis with Multiple Comorbidities Treated with Dupilumab. A Case Report and Review of the Literature Regarding the Safety of Dupilumab.使用度普利尤单抗治疗的伴有多种合并症的特应性皮炎。一例病例报告及关于度普利尤单抗安全性的文献综述
Life (Basel). 2022 Oct 21;12(10):1670. doi: 10.3390/life12101670.
6
Tissue Adhesives: From Research to Clinical Translation.组织黏合剂:从研究到临床转化
Nano Today. 2021 Feb;36. doi: 10.1016/j.nantod.2020.101049. Epub 2020 Dec 20.